FMP

FMP

Enter

INBX - Inhibrx Biosciences,...

photo-url-https://images.financialmodelingprep.com/symbol/INBX.png

Inhibrx Biosciences, Inc.

INBX

NASDAQ

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.

14.1 USD

-0.05 (-0.355%)

INBX Financial Statements

Quarter

2024 Q3

2024 Q2

2024 Q1

2023 Q4

Total Revenue

0

100k

0

1.63M

Cost of Revenue

0

475k

360k

298k

Gross Profit

0

-375k

-360k

1.34M

Operating Expenses

46.8M

161M

73.47M

89.63M

Research and Development

38.89M

67.63M

63.59M

81.84M

Selling, General & Administrative Expenses

7.9M

93.37M

9.87M

7.79M

Selling & Marketing Expenses

0

0

-104k

-46k

General & Administrative Expenses

7.9M

93.37M

9.97M

7.83M

Other Expenses

0

0

-59k

-158k

Operating Income

-46.8M

-160.9M

-73.83M

-88.29M

Total Other Income/Expenses Net

2.93M

2.02B

-4.88M

-3.69M

Income Before Tax

-43.86M

1.86B

-78.71M

-91.97M

Income Tax

0

2k

316.72k

-4k

Net Income

-43.86M

1.86B

-78.71M

-93.6M

Basic EPS

-2.84

128.35

-1.44

-1.73

EPS Diluted

-2.84

125.48

-1.44

-1.73

Basic Average Shares

15.47M

14.48M

54.55M

54.03M

Diluted Average Shares

15.47M

14.81M

54.55M

54.03M

EBITDA

-46.8M

1.86B

-73.47M

-87.99M

Retained Earning Schedule

Quarter

2024 Q3

2024 Q2

2024 Q1

2023 Q4

Retained Earnings (Previous Year)

-14.4M

-692.44M

-613.73M

-520.13M

Net Income

-43.86M

1.86B

-78.71M

-93.6M

Stock Repurchases

0

0

0

0

Dividend Paid

0

0

0

0

Retained Earnings

-58.27M

-14.4M

-692.44M

-613.73M

Other Distributions

-43.86M

678.04M

-78.71M

-93.6M

PPE Schedule

Quarter

2024 Q3

2024 Q2

2024 Q1

2023 Q4

Gross PPE

8.4M

9.62M

9.45M

9.37M

Annual Depreciation

760k

476k

360k

298k

Capital Expenditure

-247k

-1.22M

-1.12M

-3.44M

Net PPE

7.89M

10.36M

10.21M

12.52M

Intangible and Goodwill Schedule

Quarter

2024 Q3

2024 Q2

2024 Q1

2023 Q4

Acquisitions and Adjustments

0

0

0

0

Goodwill (Previous Year)

0

0

0

0

Goodwill

0

0

0

0

All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep